BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Buy Rating and New Report Issued for Plandai Biotechnology, Inc. (PLPL.OB)


9/23/2013 10:22:35 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - September 23, 2013) - Stock Market Media Group, a research and content development investor relations firm, has released its 3rd Quarter report and issued a Speculative Buy Rating on Plandaí Biotechnology, Inc. (OTCQB: PLPL). The report: Plandaí Biotechnology, Inc. - From R&D to Market, is the first in a series of reports that will follow Plandaí as it transitions from a biotech solely engaged in research and development to a company launching products into the marketplace.

Read the Plandaí Report at www.stockmarketmediagroup.com/reports.

In the new report, Stock Market Media Group looks at the latest news coming from Plandaí; including, the new Pheroid™ technology that should enhance the company's Phytofare™ brand well beyond the numbers already reported on its highly bioavailable products, the company's many clinical trials, and a look into Plandaí's near-term future.

The 4th Quarter, 2013, is just a week away and Plandaí upped the ante in the 3rd Quarter by entering into an exclusive agreement to use the Pheroid™ technology to further strengthen its products. Plandaí already boasts of the highest bioavailability numbers in the industry using its own hydrodynamic sheering process, but the company recently added the game-changing technology that will now allow it to target and deliver its highly bioavailable products to specific areas of the body without damaging the tissues.

Plandaí also announced in Q3 that it has commenced two of a number of clinical trials either underway or expected to begin in the coming months. The company will begin to use the new Pheroid™ technology in many of its trials. This report will explain each of the company's current and upcoming trials, the goals of each trial, end dates and when shareholders can expect to see the results of those trials.

With a great deal of R&D under Plandaí's belt, the report lists the first products expected to hit the market in the transition to a new future.

Read the Plandaí Report at www.stockmarketmediagroup.com/reports.

About Stock Market Media Group

Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information: www.stockmarketmediagroup.com.


Contact:
Stock Market Media Group
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES